We’re looking forward to exhibiting at the BIO Events International Convention this June. Please visit us at the Oregon Bioscience Pavilion #1225. myemail-api.constantcontact.…

Join our esteemed list of academic partners to accelerate your  cancer research with pre-clinical human data from @keliomics : 1) Advance your work to the organ-scale (e.g. work with breast cancer  in human breast tissue, complete with immune cells, stromal compartments, breast ducts, and intact human extracellular matrix). 2) Deploy true patient heterogeneity in your preclinical studies and clinical trial designs with biostatistics. 3) Clone study capabilities, no risks to patients and no regulatory requirements. Learn more about our paradigm-shifting technology at keliomics.com and message us through X/Twitter or at info@keliomics.com #adiposeresearch #tumormicroenvironment #breastcancerresearch #cancerresearch #TNBC #coloncancer #drugdevelopment #ExVivoTumors #MicrophysiologicalSystems #adiposetissue #breastcancer #epiploicadiposetissue #whiteadiposetissue #oncology #adipocytes

@keliomics ' national network of surgeons donate living, human tissues for cancer efficacy testing. We source the donor tissues, produce ex vivo tumors, and test assets based on customer specifications. We return time-lapse microscopy and advanced readouts such as transcriptomics, proteomics, lipidomics, and spatial transcriptomics. We offer the tumor tissue seen in the chart below.  (Data on file: Keliomics) Please message us at info@keliomics.com to learn more about how our proprietary technology can improve your drug development success. #tumormicroenvironment #TNBC #extracellualrmatrix #ExVivoTumors #breastcancer #CancerResearch #3DPredict #PrecisionMedicine #Chemotherapy #clinicaltrials

Kudos to @keliomics Chief Science Officer, Dr. Elizabeth Martin, for her presentation, “Ex vivo breast tumors for understanding the patient specific tumor microenvironment remodeling and drug responses,” at the @AACR 2024 Annual Meeting in San Diego, CA.  Dr. Martin demonstrated how Keliomics’ novel ex vivo breast tumors allow for 1) real-time examination of breast cancer interactions with the full human breast environment/TME and 2) analytical isolation of breast cancer-specific factors vs. patient-specific factors in the development and progression of breast cancer. #drugdevelopment #ExVivoTumors #tumormicroenvironment #adiposeresearch #cancerresearch #oncology #biopharma #biotech #AACR2024

Join @keliomics CEO & Co-Founder Frank Lau on March 27th for the @OccamPoint webinar “A Breakthrough Organ-Scale Biology Platform for Drug Development.” Dr. Lau will discuss Keliomics’ paradigm-shifting technology that keeps human tissues and tumors alive outside the human body for 8 weeks.  A live Q&A session will follow.  More details and registration at events.zoom.us/ev/AkSsGUHCML….  Sponsored by Stat4ward and Clinical Research Strategies #tumormicroenvironment #TNBC #extracellualrmatrix #ExVivoTumors #breastcancer #CancerResearch #3DPredict #PrecisionMedicine #Chemotherapy #clinicaltrials

@keliomics ' proprietary ex vivo platform reduces the risk, time, and cost of preclinical solid-tumor oncology drug development.  Our paradigm-shifting technology reliably allows testing against  tumors in living human tissue outside the human body.  Keliomics sources the donor tissues, produces the ex vivo tumors, and tests assets based on customer specifications. This disruptive technology enables, for the first time, human testing before human subjects.  How can we help your work? info@keliomics.com. #adiposeresearch #tumormicroenvironment #breastcancerresearch #cancerresearch #TNBC #coloncancer #drugdevelopment #ExVivoTumors #epiploicadiposetissue #whiteadiposetissue #oncology #adipocytes #adiposetissue #breastcancer

Ninety-five percent of all investigational cancer drugs fail in clinical trials.  To help remedy this critical issue, the @NIH and @US_FDA established the Microphysiological Systems Program to accelerate the development of more predictive preclinical models. @keliomics ' breakthrough technology enables the stable, ex vivo culture of whole human tissues for at least 8 weeks. Our technology is ideal for pre-clinical efficacy testing and clinical trial planning planning by showing which therapies are most effective against the patients' tumors. Learn more at keliomics.com.  #tumormicroenvironment #TNBC #extracellualrmatrix #ExVivoTumors #breastcancer #CancerResearch #3DPredict #PrecisionMedicine #Chemotherapy #clinicaltrials

Check out Frank Lau, MD, CEO and Co-Founder of @keliomics , with the Price of Business podcast host @KevinPriceLive , discussing how ex vivo tumors (EVTs) help biopharmaceutical companies select the best new therapeutics to advance into clinical trials. These EVTs leapfrog current technologies by growing tumors in donated human tissues, such as breast cancer in human breast tissue. This disruptive technology enables, for the first time, human data before human testing.  usadailytimes.com/2024/01/29… #adiposeresearch #tumormicroenvironment #breastcancerresearch #cancerresearch #TNBC #coloncancer #drugdevelopment #ExVivoTumors #epiploicadiposetissue #whiteadiposetissue #oncology #adipocytes #adiposetissue #breastcancer

As a leader in advancing breast cancer research, @keliomics applauds the advances made in the field in 2023. Check out @drsarahsam & @VKaklamani review the highest impact science of 2023 in breast cancer research recently on @SABCSSanAntonio Snippets program, as well as their expectations of new treatment options on the horizon. @DFCI_BreastOnc; @utswcancer; @DanaFarber; @MDAndersonNews; @UTHealthSA; @UTHealthSAMDA #tumormicroenvironment #TNBC #extracellualrmatrix #ExVivoTumors #CancerResearch